These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21373894)

  • 1. The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats.
    Rao VA; Zhang J; Klein SR; Espandiari P; Knapton A; Dickey JS; Herman E; Shacter EB
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1125-34. PubMed ID: 21373894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
    Hasinoff BB; Patel D
    J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.
    Rao VA; Klein SR; Agama KK; Toyoda E; Adachi N; Pommier Y; Shacter EB
    Cancer Res; 2009 Feb; 69(3):948-57. PubMed ID: 19176392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
    Noulsri E; Richardson DR; Lerdwana S; Fucharoen S; Yamagishi T; Kalinowski DS; Pattanapanyasat K
    Am J Hematol; 2009 Mar; 84(3):170-6. PubMed ID: 19140186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
    Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
    Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo.
    Lee JC; Chiang KC; Feng TH; Chen YJ; Chuang ST; Tsui KH; Chung LC; Juang HH
    Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27589737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
    Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
    Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential cardiotoxicity in response to chronic doxorubicin treatment in male spontaneous hypertension-heart failure (SHHF), spontaneously hypertensive (SHR), and Wistar Kyoto (WKY) rats.
    Sharkey LC; Radin MJ; Heller L; Rogers LK; Tobias A; Matise I; Wang Q; Apple FS; McCune SA
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):47-57. PubMed ID: 23993975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.
    Deng S; Yan T; Jendrny C; Nemecek A; Vincetic M; Gödtel-Armbrust U; Wojnowski L
    BMC Cancer; 2014 Nov; 14():842. PubMed ID: 25406834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproductive hormone levels and differential mitochondria-related oxidative gene expression as potential mechanisms for gender differences in cardiosensitivity to Doxorubicin in tumor-bearing spontaneously hypertensive rats.
    Gonzalez Y; Pokrzywinski KL; Rosen ET; Mog S; Aryal B; Chehab LM; Vijay V; Moland CL; Desai VG; Dickey JS; Rao VA
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):447-59. PubMed ID: 26108538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron chelator-induced up-regulation of Ndrg1 inhibits proliferation and EMT process by targeting Wnt/β-catenin pathway in colon cancer cells.
    Chen Z; Sun J; Li T; Liu Y; Gao S; Zhi X; Zheng M
    Biochem Biophys Res Commun; 2018 Nov; 506(1):114-121. PubMed ID: 30340826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin.
    Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC
    Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.
    Krishan S; Richardson DR; Sahni S
    Biochim Biophys Acta; 2016 Dec; 1863(12):2916-2933. PubMed ID: 27639899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism.
    Gundelach JH; Madhavan AA; Wettstein PJ; Bram RJ
    FASEB J; 2013 Feb; 27(2):782-92. PubMed ID: 23134680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.
    Yalowich JC; Wu X; Zhang R; Kanagasabai R; Hornbaker M; Hasinoff BB
    Biochem Pharmacol; 2012 Jul; 84(1):52-8. PubMed ID: 22503743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trypanotoxic activity of thiosemicarbazone iron chelators.
    Ellis S; Sexton DW; Steverding D
    Exp Parasitol; 2015 Mar; 150():7-12. PubMed ID: 25595343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
    Voest EE; van Acker SA; van der Vijgh WJ; van Asbeck BS; Bast A
    J Mol Cell Cardiol; 1994 Sep; 26(9):1179-85. PubMed ID: 7815460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin-induced cardiotoxicity is suppressed by estrous-staged treatment and exogenous 17β-estradiol in female tumor-bearing spontaneously hypertensive rats.
    Pokrzywinski KL; Biel TG; Rosen ET; Bonanno JL; Aryal B; Mascia F; Moshkelani D; Mog S; Rao VA
    Biol Sex Differ; 2018 Jun; 9(1):25. PubMed ID: 29907135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity.
    Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.